• As of 24th of October DFE Pharma offers a new specialty grade SuperTab® 40LL. SuperTab® 40LL is the newest product in DFE Pharma’s extensive direct compression portfolio composed of (anhydrous) lactose (95% w/w) and lactitol monohydrate (5% w/w). more >
    Tuesday, October 24, 2017
  • For the 5th year in a row DFE Pharma is organising the Dry Powder Inhalation China technology conference in Shanghai, China. more >
    Friday, February 10, 2017
  • From 17 to 21 April 2016 DFE Pharma will be present in Phoenix, Arizona for RDD (Respiratory Drug Delivery). RDD addresses all aspects of drug delivery to the lungs and nose for treatment of local and systemic diseases. more >
    Thursday, April 7, 2016
  • As a follow up to the three successful editions with 130 inhalation industry professionals, DFE Pharma will organise the 4th Dry Powder Inhalation China Technology Conference held in Shanghai, China. more >
    Thursday, March 3, 2016
  • As of 1 November 2015, Bas van Driel has been appointed Chief Executive Officer (CEO) of DFE Pharma. He will take over Jan Jongsma’s responsibilities. Bas van Driel will continue the pursuit of DFE Pharma to be leading in excipient excellence. more >
    Friday, November 20, 2015
  • In October, DFE Pharma will be present at a leading pharmaceutical industry event, AAPS (American Association of Pharmaceutical Scientists). At AAPS in Orlando, USA, DFE Pharma will uncover the synergy between Lactose and Microcrystalline Cellulose (MCC). more >
    Wednesday, October 21, 2015

News archive

Media inquiries
For media inquiries please click here